An exceptionally attractive target for drug discovery and development
Dublin, July 25, 2022 (GLOBE NEWSWIRE) — The “Claudin 6: a target opportunity to develop effector-enhanced drug modalities” report has been added to from ResearchAndMarkets.com offer.
Claudin 6 (CLDN6) is a compelling tumor antigen. The tetraspan membrane protein is a member of the claudin family of tight junction proteins. CLDN6 is an oncofetal tight junction molecule that is expressed during embryonic and fetal development, transcriptionally silenced in adult tissues, and reexpressed on the surface of several epithelial cancers. The transmembrane protein CLDN6 is practically absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.
Although it is an attractive target due to its exceptionally selective expression of cancer cells, therapeutic monoclonal antibodies targeting CLDN6 are difficult to discover due to the abundance of closely related family members and a absolute need for high specificity. Many claudin family proteins have high sequence identity. Most similar to CLDN6 is CLDN9, and the two proteins differ by only three of 76 residues in their extracellular loops, creating a challenge for the development of highly selective CLDN6 antibodies.
This report describes and analyzes in May 2022
The scientific rationale for CLDN6-targeted therapies based on the characteristics of the target and its differential expression profile;
Preclinical proof of concept of different CLDN6-targeted drug modalities;
Clinical experience with CLDN6 targeted therapies;
Clinical indications suitable for the development of therapies targeted at CLDN6 and their patient populations;
The competitive landscape of CLDN6 targeted drug development modalities;
Specific profiles of drug modalities targeted at CLDN6; and
Profiles of companies active in the development of anti-CLDN6 therapy candidates.
Effector-enhanced antibodies and cells such as antibody-drug conjugates, chimeric antigen-receptor (CAR) T-cells, and bispecific antibodies that redirect T-cells or specifically activate T-cells will be activated and benefit from the antigen profile. selective expression of cancer and high target selectivity to avoid on-target and off-tumor toxicity.
Despite the technical challenge, new cellular and humoral drug modalities targeting CLDN6 have emerged and the first product candidates have entered clinical development. The fact that preliminary clinical experience shows high anti-tumor activity of the first drug candidate and the competitive field is still limited, makes claudin 6 an exceptionally attractive target for drug discovery and development.
Main topics covered:
1 Target Background
2 Target antigen expression profile
3 Preclinical proof of concept
4 Clinical experience with CLDN6-targeted drug modalities
5 Clinical indications and patient populations
6 Competitive Landscape and Drug Modalities
7 candidate profiles in drug and cell therapy
7.1 CAR T cells
7.2 Antibody-drug conjugates (ADCs)
7.3 Bispecific T cell redirecting antibodies
7.4 Bispecific antibodies activating T cells
7.5 Modes of drug failure
8 company profiles
For more information on this report, visit https://www.researchandmarkets.com/r/4zrcb1
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900